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Development of a Simple Chromogenic Factor VIII Assay for
Clinical Use
R.J. Wagenvoord, H.H. Hendrix, H.C. Hemker
Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
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Abstract. The aim of this study was the development of a simple chromogenic factor VIII
assay for practical clinical use. The criteria that the assay fulfils are: (1) The method is so
sensitive that even l0lo factor VIII in human plasma is easily detected. (2) The method is
linear in the amount of factor VIII from 0 to 2000/o in plasma. (3) The pipetting scheme is
very simple; two reagents are prepared, reagent I (factor IXa, thrombin, Ca2* and phospho-
lipids) and reagent 2 (factor X). Then we pipet at t : 0 s, 100 pl diluted plasma + 100 pl
reagent 1 in a reaction tube; at t : 30 s, 100 pl reagent 2 in the same tube and at t: 90 s,
200 pl of the reaction mixture in a cuvette with 700 pl EDTA buffer (stop buffer) and the
formed factor Xa is measured with a chromogenic substrate. (4) The reaction components
are stable during at least a whole working day. Factor VIII was measured in an assay using
bovine clotting factors, so one avoids the risk of viral infections, which one might catch by
working with clotting factors isolated from human plasma.
Introduction
For practical clinical use we developed an
assay for factor VIII in human plasma. Some
work concerning the development of this as-
say [] and its practical use [2] was already
presented at the congress on Thrombosis
and Haemostasis in Brussels, 1987. In order
to be of practical suitability, the assay must
be very sensitive (less then l0lo factor VIII
must be detectable), the assay must be linear
from 0 to 2000/o factor VIII in plasma, the
pipetting steps should be as minimal as pos-
sible and the reaction components should be
stable during a whole working day.
The activation of the zymogen factor X
into factor Xa by the serine protease factor
IXa [review in ref. 3] is strongly increased by
negatively charged phospholipids, Ca2* ions
and activated factor VIII [review on factor
VIII in ref.4l. The complex of factor IXa,
factor VIIIa, Ca2* and phospholipids is
called the intrinsic factor X activating com-
plex, or intrinsic factor X activator [5-9].
Van Dieijen et al. [0] described the condi-
tions for optimal interaction of bovine factor
VIIIa in the assembly of the factor X activat-
ing complex. In their article they showed
that a complete factor X activating complex
will activate about 900 molecules factor X
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per minute. Thus, under conditions that the
activated factor VIII is completely bound in
the factor X activating complex, 900 mole-
cules factor Xa are formed per minute per
molecule factor VIIIa. Factor Xa can be
measured with a chromogenic substrate. So,
if one chooses the right conditions a small
amount of factor VIIIa can form a large
amount of factor Xa and in this way a sensi-
tive factor VIII assay is obtained. However,
we deal with human factor VIII which may
act differently from bovine factor VIII, for
which the optimal conditions for a good
assay are described [10]. There are two pos-
sible approaches, one can use either human
clotting factors, or bovine clotting factors in
the factor VIII assay. We strongly favored
the use of bovine clotting factors for the fol-
lowing reasons. Bovine blood is easy to ob-
tain in large quantities in contrast to human
blood, isolation procedures for the purifica-
tion of bovine clotting factors are well de-
scribed and finally one avoids the risk of
viral infections using bovine plasma instead
of human plasma.
We investigated if bovine clotting factors
are suitable for a human factor VIII assay,
which was proven to be the case. To obtain a
system as sensitive as possible we have var-
ied each of the reaction components of the
factor X activating complex to determine
their optimal concentrations.
FVIIIa .  FIXa . Ca2' PL
^ " (factor X activating complex)
We successively searched for the optimal
conditions for factor VIII activation with
thrombin, the optimal factor IXa concentra-
tions to bind all factor VIIIa, the optimal
phospholipid concentration and composition
to obtain a rapid factor Xa formation and
frnally the optimal pH for factor X activation.
To determine the required factor X concen-
tration we measured its K. for the complex.
When all conditions were optimal, a turnover
rate was obtained of 1,400 mol factor Xa
formed per minute and mole faotor VIIIa. We
also investigated the suitability of the chromo-
genic substrate (CH:OCO-D-CHG-GIy-Arg-
pNA-AcOH) for the assay. It was shown that it
is suitable for our purposes, however, a throm-
bin inhibitor o-NAPAP [N-o-(2-naphtylsulfo-
nylelycyl)-D, Z-amidinophenyl-alanine-piper-
idide hydroididel should be added, to inhibit
the large amount ofthrombin which is present
in the assay mixture for complete factor VIII
activation.
Stability studies showed lyophilized re-
agents could be stored for several months
without loosing their activity and that recon-
stituted reagents were stable for at least a
whole working day. Moreover, we showed
that the assay was linear from 0 to 2000/o fac-
tor VIII in plasma and that less than lo/o fac-
tor VIII could be well detected.
Materials and Methods
Materials
Fxa-substrate (CH3OCO-D-CHG-GIy-Arg-pNA-
AcOH) and o-NAPAP [N-o-(2-naphtylsulfonylgly-
cyl)-D,I-amidinophenyl-alanine-piperidide hydroi-
didel were obtained from Pentapharm, Switzerland;
DEAE-Sephadex and Sepharose-4B were from Phar-
macia, Sweden; Heparin-Agarose was kindly donated
by T. Janssen-Claessen.
All other reagents were of the highest grade avail-
able and were supplied by either Merck (FRG) or
Sigma (USA).
Phospholipids and Phospholipid vesicles
Phosphatidyl choline was extracted from egg yolks
according to Bligh and Dyer [11] and purified as
described by Comfurius and Zwaal [12]. Phosphatt-
dyl serine and phosphatidyl ethanolamine were pre-
pared in a similar way, however, extracted from bo-
r98 Wagenvoord/Hendrix/Hemker
vine brains. Vesicles were prepared by sonication ofa
phospholipid mixture in a buffer containing 50 mM
Tris-HCl and 175 mM NaCl (pH 7.9) using an MSE
Mark II 150-Watt ultrasonic disintegrator set at 9 p
peak to peak amplitude. The composition of the vesi-
cles was 75 mol0/o phosphatidyl choline and 25 mol0/o
phosphatidyl serine or as indicated.
Proteins
Bovine factor X was isolated according to Fuji-
kawa et al. [ 3] and bovine factor IXa as described by
van Dieijen et af. [8]. Thrombin was prepared as
described by Wagenvoord et al. [4]. As reference
plasma (1000/o factor VIII) a normal pooled citrated
plasma was used that was prepared from 15 healthy
donors (donated by T. Janssen-Claessen). Congenital
factor VIII deficient plasma was kindly donated by T.
Repucci (Centre de Transfusion, Lidge, Belgium).
Plasmas containing more than 100 0/o factor VIII were
prepared by mixing reference plasma with a cryopre-
cipitate (10 U/ml).
Results
Properties of the Chromogenic Substrate
C H 3 O C O-D - C H G- G ly -Ar g- p NA- Ac O H
We have studied the kinetic properties of
the factor Xa substrate CH3OCO-D-CHG-
Gly-Arg-pNA-AcOH (FXa-substrate). First
we determined the kinetic constants of FXa-
substrate hydrolysis by factor Xa. For that
reason a Lineweaver-Burk plot was made
(fig. 1a). For K- we measured 142 pM and
V-"* was 386 nM p-nitroanilide liberated/
s.n-41 factor Xa, or 229.5 milliabsorbance
units/nM factor Xa.min. Remarkable is the
effect of a high NaCl concentration on Km,
which becomes 27.3 StM in the presence of
2.5 MNaCl, V-u*, however, does not change
by the increased NaCl concentration. Thus,
by addition of NaCl the affrnity of the FXa
substrate for factor Xa increases, which leads
to a higher rate ofhydrolysis.
Since in the factor VIII assay mixture a
large amount of thrombin is present, it was
necessary to determine the kinetic constants
of the FXa substrate hydrolysis by thrombin.
Figure lb shows that FXa substrate is hydro-
lysed by thrombin, however, much slower
than factor Xa. V-* is 12.6 nM p-nitroani-
lide liberated/s.nM thrombin or 7.52 rnll-
liabsorbance wits/nM thrombin.min and
K- is 59.0 1tM. ln reagent 1 of the FVIII
assay a large amount of thrombin is present
(frg. 6), which causes a very rapid hydrolysis
of the FXa substrate, so it cannot be used
unless an effective thrombin inhibitor is
present which does not inhibit factor Xa.
Figure 2 shows that the thrombin inhibi-
tor a-NAPAP is able to inhibit thrombin
effectively without inhibiting factor Xa very
much. At a concentration of I pM a-
NAPAP, thrombin is inhibited by 99.5o/o,
but factor Xa only by lo/0. By using I pM
a-NAPAP (final concentration in the cu-
vette), the hydrolysis rate of FXa-substrate
by thrombin is brought back to 2l.8nM/
min, which is only 10/o of the rate to be
expected by the factor Xa formed in an assay
with normal plasma.
On basis of the results of figures 1 and 2
factor Xa was measured by addition of
100 pl FXa substrate (800 pl[) plus l01tM
o-NAPAP to 900 pl of a factor Xa sample.
Preparation of a Factor VIII Assay
Mixture
Our frrst goal was the preparation of a
mixture containing the purified bovine clot-
ting factors which could detect human
plasma factor VIII as sensitive as possible,
therefore we varied each of the components
of the factor X activating complex to deter-
mine their optimal concentration.
In frgure 3a we studied the effect of
thrombin on factor VIII activation in human
plasma. Maximal factor VIII activation oc-
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Fig. 1. Lineweaver-Burk plots of FXa-substrate
hydrolysis'by factor Xa and thrombin. a Plot of FXa-
substrate hydrolysis by factor Xa. The factor Xa con-
centration was I nM. c : The experiment was done in
standard buffer (175 m-\r' NaCl, 50 mM Tris-HCl
(pH 7.9), 0.5 mglml human serum albumin); a : ex-
periment in which a buffer with 2.5 M NaCl is used.
b Plot of FXa-substrate hydrolysis by thrombin. The
thrombin concentration was 1 nM and standard
buffer was used.
curs at thrombin concentrations of 30 nM or
more. The presence of more lhan 30 nM
thrombin does not lead to more factor VIIIa
formation, however, it is preferable to have a
Iarge excess of thrombin in the assay because
of the presence of antithrombin III and cl2-
macroglobulin in the plasma, which will inac-
Fig.2. Effect of o-NAPAP on FXa-substrate hy-
drolysis by factor Xa and thrombin. The cuvette con-
tained 20 n,41thrombin (o) or 0.75 nM factor Xa ( ),
80 pM FXa-substrate and o-NAPAP. The increase of
the absorption at 405 nm was measured at 37'C. The
activities in the absence of o-NAPAP were taken as
100 o/0.
tivate the thrombin. An additional advantage
of excess of thrombin is that it will saturate all
plasma serine protease inhibitors and thus
formed factor Xa is not inactivated.
Figure 3b shows the effect of factor IXa
concentration on the factor Xa formation by
the factor X activating complex. The reac-
tion rate is a reflection of binding of factor
VIIIa into the complex. The frgure shows
that optimal binding occurs when the factor
IXa concentration is 50 nM or higher.
In figures 3c and d the effect is shown of
phospholipids on the activation of bovine
factor X by the factor X activating complex
composed of bovine factor IXa, human fac-
tor VIIIa and Ca2*. Figure 3c shows the ef-
fect of varying amounts of phosphatidyl ser-
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Fig. 3. Optimization of the human factor VIII as-
say. a Activation of human plasma factor VIII with
thrombin: to 200 pl factor IXa (200 nM), CaClz (10
mM), phospholipids (40 1tM;75 molo/o phosphatidyl
choline, 25 molo/o phosphatidyl serine) 100 pl throm-
bin were added. At t : 0 s 50 pl l0 times diluted human
plasma were added and at t : 30 s 50 pl factor X
(2 ttM).Samples of 300 pl were taken at t : 60 s and
the factor Xa formation was measured. To stop further
factor Xa formation the samples were pipetted into
600 pl EDTA (20 mM). b Effect of the factor IXa con-
centration on the rate offactor Xa formation: to 200 pl
thrombin (100 nM), CaCIz (10 m,4.r'), phospholipids
(OpM; 75 molo/o phosphatidyl choline, 25 molo/o
phosphatidyl serine) I 00 pl factor IXa were added. At
t : 0 s 50 pl 10 times diluted human plasma were added
and at t: 30 s 50 pl factor X(2 1tM). Samples of 300 pl
were taken at t = 90 s and the factor Xa formation was
measured. c, d Effect of phospholipid composition and
concentration on the rate of factor Xa formation: to
200 pl thrombin (200 nM), CaCl2 (10 mM),factorlXa
(200 nM) I00 pl phospholipids were added. At t : 0 s
50 pl l0 times diluted human plasma were added and
at t : 30 s 50 pl factor X (2 ttM). Samples of 300 pl
were taken at t: 90 s to measure the formed factor Xa.
c The vesicles concentration was kept at 20 1tM,
whereas the composition was varied. The phosphatidyl
serine content was 0-50 molo/o and the phosphatidyl
choline content 100-50 mol0/0. d Effect of phospho-
lipid concentration on the rate of factor Xa formation.
The vesicle composition was kept at 25 molo/o phos-
phatidyl serine and '15 molo/o phosphatidyl choline.
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Fig.4. Lineweaver-Burk plot of factor X activa-
tion by the factor X activating complex composed of
bovine factor IXa and human factor VIIa. To 200 pl
thrombin (2OOIM\ CaClz (10mM), factor IXa
(200 nM) phospholipids (40 pM; 25 molo/o phospha-
tidyl serine, 75 molo/o phosphatidyl choline) at t: 0 s
100 pl 20 times diluted human plasrna were added. At
t :  30s 100p1 factor X (67-800nM) were added.
Samples of 300 pl were taken at t : 90 s to measure
the formed factor Xa.
ine in the vesicles (fixed concentrations) on
the factor X activating reaction: maximal
activity is found at a phosphatidyl serine
concentration of around 25 molo/o. In fig-
ure 3d one can observe a rapid increase of
the enzymatic activity when the phospho-
lipid concentration (with fixed composition)
increases from 0 to l0 1tM, then becomes
maximal and subsequently slows down at
still higher phospholipid concentrations.
This result is in agreement with an earlier
report [8], however, valid for proteins which
all were isolated from bovine blood.
We also have investigated the effect of
phosphatidyl ethanolamine and cholesterol
addition to the vesicles. When a phosphati-
dyl choline/phosphatidyl serine ratio of 3 is
maintained and either phosphatidyl ethanol-
amine or cholesterol is added, there is no
effect at low concentrations of both com-
pounds. However, when phosphatidyl etha-
nolamine is present in a concentration of
more than 15 mol0/0, the activity of the vesi-
cles drops. For cholesterol the same effect is
found at concentrations of more than 200/o
(dw). So we can conclude that vesicles of a
composition of 25 mol0/o phosphatidyl serine
and 75 mol0/o phosphatidyl choline have an
optimal activity, which cannot be improved
by addition of other compounds.
Figure 4 shows the Lineweaver-Burk plot
of factor X activation by the complete factor
X activating complex. The two kinetic pa-
rameters that can be derived from the figure
are K-, which is 31.4 nM,andV-"*, which is
241 milliabsorbance units/min, when a 20
times diluted reference plasma is used
(11.7 nM factor Xalmin).
We also have investigated the effect of the
pH on the complete factor X activating com-
plex (containing bovine factors, but human
factor VIIIa). The activity showed a broad
maximum between pH 7.6 and 8.5, whereas
at lower and higher pH values the activity
decreased. As a result of these experiments
we decided to use buffers with pH 7.9.
In frgure 5 we have measured factor Xa
formation by time in an assay containing the
human factor VIII and the other components
of the factor X activating complex, which
were present in optimal concentrations as
judged from figures 3 and 4. Two reagents
were prepared: reagent l, containing 300nM
factor IXa, 300rLM thrombin, 15 mM CaClz
and 60 pM phospholipid vesicles (75 molo/o
phosphatidyl choline and25 mol0/o phospha-
tidyl serine) and reagent 2 containing I pM
factor X. By mixing I part reagent l, I part
diluted plasma and I part reagent 2, the final
concentrations ofeach ofthe clotting factors
were optimal for maximal factor Xa forma-
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Fig.5. Linearity of the factor X activating reac-
tion. To 1 ml of 300 nM factor IXa, 300 n,41 throm-
bin, 60 pM phospholipids (75 mol0/o phosphatidyl
choline, 25 mo10/o phosphatidyl serine), l5 mM CaClz
at t = 0 s 1 ml 100 times diluted human plasma was
added. At t : 30 s I ml factor X (1 ttM) was added.
Samples of 200 pl were taken in time to measure
formed factor Xa.
Fig.6. Stability of lyophilized FVIII-assay re-
agents. Two reagents were lyophilized in amounts
of I ml. Reagent I contained 300nM factor IXa,
tion. The solutions were made in a buffer
containing l7 5 mM NaCl, 50 mM Tris-HCl,
0.5 mg/ml ovalbumin (pH 7.9). In figure 5 it
is shown that factor Xa formation by time is
linear up to 1.5 min, but then the rate of fac-
tor Xa formation decreases.
Stabilily of the Factor VIII Assay
Reagents
A point of practical importance is the sta-
bility of the reagents after preparation, lyo-
philization, storage and reconstitution. We
prepared reagents I and 2. Reagent I con-
taining 300 nM thrombin, 300 nM factor
300nM thrombin, 15 mM CaC12, 60 pM phospho-
lipid vesicles (75 molo/o phosphatidyl choline, 25
molo/o phosphatidyl serine) and reagent 2 contained
I pM factor X. The activities of the reagents were
tested before (o) and after lyophilization, storage at
4'C and reconstitution (o). The pipetting sequence
was that at t : 0 s 100 pl reagent I were mixed
with 100 prl 20 times diluted human plasma, at t :
30 s 100 pl reagent 2 were added and at t : 60 s
200-pl samples were taken to measure formed fac-
tor Xa.
IXa, l5 mM CaCl2 and 60 pM vesicles (75
mol0/o phosphatidyl choline and 25 molo/o
phosphatidyl serine), was lyophilized in por-
tions of 2 ml. Also reagent 2 containing
I pM factor X was lyophilized in this way.
Both reagents were stored aI 4'C. After re-
constitution they were tested. We deter-
mined the protein concentrations in the re-
agents and the activity ofthe reagents in the
factor VIII assay.
We determined the thrombin and factor
IXa concentration in reagent I after recon-
stitution. The thrombin concentration var-
ied from 258 to 290nM and the factor IXa
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Fig. 7. Linearity of the FVIII assay. Plasmas were
prepared containing 0-200o/o factor VIII (normal
pooled plasma : 1000/0) which were diluted 10 times.
The reagents described in figure 6 were used and the
same pipetting sequence was done, however, 200-pl
samples were taken at 90 s.
concentration from 281 to 295nM. After
reconstitution we measured the factor X
concentration in reagent 2, which was 0.8-
I.0 1tM. Also in this case there was not much
loss ofactivity. Because the concentration of
the proteins was chosen so that small
changes in their concentration would not ef-
fect the factor VIII assay, we expected no
change in the activity. In figure 6 this is
shown. Before lyophilization and after re-
constitution the activity was the same and,
moreover, the activity remained at the start-
ing level e\/en after half year of storage of the
lyophilized reagents.
We also tested the stability of the reagent
after reconstitution during the working day
and after storage at 4 " C during the night. The
activities are expressed in percentages: before
lyophilization, 1000/o; n day 1, after reconsti-
tution of the reagents, the activities were
1010/o at 10.00 h and l0l 0/o at 11 .00 h. At day
3 at 11.00 h, the activity was 930/0. In other
experiments imilar results were found.
Sensitivity of the Factor VIII Assay
Finally we have tested the sensitivity of
the chromogenic factor VIII assay by mea-
suring plasmas containing 0-2000/o factor
VIII. In figure 7 the results ofthese tests are
shown. One can observe a complete linearity
between the factor VIII content of the
plasma and the factor Xa formation in the
reaction mixture. Plasma containing lo/o fac-
tor VIII gives rise to a 2-3 times higher fac-
tor Xa formation than fully factor VIII defr-
cient plasma, so one cair easy measure I o/0
factor VIII in plasma. Using the same dilu-
tions it is possible to measure 2000/o without
underestimating the reaction rate. When we
use normal pooled plasma (1000/o factor
VIII), about 12 nM factor Xa is formed in
the assay mixture, so in the cuvette 2.4 nM
factor Xa will be present, which gives an
increase in absorbance of about 200 milliab-
sorbance units/min under the described
reaction condition.
Discussion
In this article we described the develop-
ment of a chromogenic factor VIII assay,
which can be done in only a few pipetting
steps. The test is linear from 0 to 200o/o fac-
tor VIII in human plasma. The reagents are
stable when they are lyophilized for at least
half a year and after reconstitution they do
not loose activity during a whole working
day. After reconstitution they can be stored
at 4"C and used during at least 3 days.
Because of its simplicity the test can be auto-
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mated. A suggestion to minimize the pipet-
ting steps is to mix the diluted plasma with
factor X (reagent 2) and add the reagent I to
this mixture. Then stop the reaction after l-
1.5 min with the EDTA buffer. When this
sequence of pipetting is used, only two steps
should be done at fixed times. In this case
factor VIII activation precedes the forma-
tion of the complete factor X activating com-
plex. However, this is not a real problem,
because the time necessary for complete fac-
tor VIII activation is only a few seconds,
since thrombin is present in high concentra-
tion and when the lag time is the same for all
factor VIII concentrations, the linearity of
the measurement is fully maintained.
If we compare human factor VIII with
bovine factor VIII in respect o their action in
the factor X activating complex, their resem-
blance is very close. The turnover rate ofthe
factor X activating complex composed of
only bovine factors is about 900 min-t [0].
We can estimate this number from our re-
sults. In human plasma about 0.25 nM factor
VIII is present [10], so in the assay offigure 6,
4.2 pM factor VIIIa is present which gives a
rate of 6 nM FXa/min. so the turnover num-
ber is about 1,400 min-1, a value which is in
the same order as was found for the bovine
factor X activating complex.
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